#ComplianceConversations with Sarah & Leslie
Analyzing the OIG Special Fraud Alert on Speaker Programs
Tuesday,
January 21, 2020
at 01:00PM-02:00PM EST
Watch Recording
Join us for this informative and interactive webinar!
Sarah diFransesca is an essential resource for individuals and companies navigating the ever-changing industries of health care and life sciences. Her practice focuses on complex health care litigation, investigations, regulatory compliance, and fraud and abuse.
Leslie Restanio is an accomplished legal professional with extensive experience leading compliance organizations. She has a strong background in pharmaceutical and healthcare law, food and drug law, commercial strategy and business operations across all aspects of drug development, approval and commercialization.
Mohammad Ovais is the Founder & CEO at qordata and has spent a decade building analytical solutions and applications for Fortune 1000 companies. Prior to this, he served as the Managing Partner/Co-Founder at Streebo. With a Bachelor in Computer Science from Rice University and EMP from MIT, he serves on the board of Entrepreneur Organization as Strategic Alliances Chair.
Overview:
In November 2020, the US Department of Health and Human Services Office of Inspector General (OIG) issued a Special Fraud Alert that draws attention to potential fraud and abuse risks for speaker programs. Life Sciences companies can utilize this guidance to evaluate their speaker remuneration in light of the risks highlighted in the Special Fraud Alert. This webinar will analyze the Special Fraud Alert followed by a Q&A session.
Key Takeaways:
• Analysis of the Special Fraud Alert guidance in conjunction with Anti-Kickback Statute enforcement of speaker programs
• Framework to evaluate current speaker programs based on risks highlighted in the Special Fraud Alert
• A walk-through of potential fraud or abuse legal theories
• Key considerations for speaker programs to reduce fraud and abuse risks
• Implications of Special Fraud Alert for the Life Sciences industry
Who should attend?
Legal and compliance professionals, consultants dealing with Compliance Monitoring and/or HCP engagement at drug or medical device manufacturing companies.
Previous
Next
